[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"onychomycosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:onychomycosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100553393","phase-1-isotretinoin-versus-excimer-light-an-adjuvant-in-treating-onychomycosis-100553393",false,"NCT06485505","Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis","Efficacy of Low Dose Isotretinoin Versus Excimer Light as an Adjuvant for Itraconazole in Treatment of Onychomycosis: a Randomized Controlled Trial.","Inclusion Criteria:\n\n* patients with onychomycosis\n\nExclusion Criteria:\n\n* pregnant and lactating females patients on statin therapy or photosensitizing drugs patients with liver disease, heart disease and diabetes milletus.","ALL","18 Years","60 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","3 groups of patients with onychomycosis will be recruited. Group A will receive itraconazole alone. Group B will receive itraconazole + low dose isotretinoin and group C will be treated with itraconazole + excimer light sessions.",[27],"Onychomycosis","RECRUITING","2026-04-19",{"date":31,"type":32},"2026-04-23","ACTUAL",{"date":34,"type":32},"2024-07-12",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Zagazig University","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100569100","clinical-investigation-for-the-evaluation-of-efficacy-and-safety-of-two-products-for-the-treatment-of-onychomycosis-100569100","NCT06689852","CLINICAL INVESTIGATION FOR THE EVALUATION OF EFFICACY AND SAFETY OF TWO PRODUCTS FOR THE TREATMENT OF ONYCHOMYCOSIS","MULTICENTRIC, RANDOMIZED, EVALUATOR BLINDED CLINICAL INVESTIGATION FOR THE EVALUATION OF EFFICACY AND SAFETY OF TWO PRODUCTS FOR THE TREATMENT OF ONYCHOMYCOSIS","Inclusion Criteria:\n\n* 1\\. Patient having given freely her\u002Fhis informed, written consent. 2. Patient having a good general health. 3. Age: between 18 and 70 years; 4. Patient with superficial onychomycosis on at least one great toenail or fingernail (for at least 10% in each arm) or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement \\<2\u002F3 of the tablets).\n\n  5\\. Patient with positive KOH staining. 6. Patient cooperative and aware of the products modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.\n\n  7\\. Patient being psychologically able to understand information and to give their\u002Fhis\u002Fher consent.\n\n  8\\. Patient having stopped any systemic antifungal treatment since at least 6 months before screening and\u002For any topical antifungal treatment since at least 3 months before screening.\n\n  9\\. Patient who agree to refrain from receiving pedicure\u002Fmanicure, artificial nails and\u002For cosmetic nail varnish or other medication on the nail being treated for the entire study duration.\n\n  10\\. Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after study end.\n\nExclusion Criteria:\n\n\\- 1. Pregnant, breastfeeding woman or woman planning a pregnancy during the study; 2. Patient considered by the investigator likely to be non-compliant with the protocol. 3. Patient enrolled in another clinical trial or which exclusion period is not over. 4. Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk; 5. Patient suffering from a severe or progressive disease (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology… 6. Patient having a known allergy or hypersensitivity to one of the constituents of the tested products.\n\n7\\. Patient with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).","70 Years",{"count":50,"type":21},88,[52],"NA","The efficacy and safety of ENRICHED (X92001591) will be evaluated in a multicentric, randomized, evaluator blinded clinical investigation in 88 patients.",[27],[56],"onychomycosis","2025-09-02",{"date":59,"type":32},"2025-09-03",{"date":61,"type":32},"2024-10-30",{"date":63,"type":21},"2026-04",{"name":65,"class":66},"Oystershell NV","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100595554","fractional-co-laser-or-40-urea-with-topical-fluconazole-microemulsion-in-onychomycosis-100595554","NCT07033962","Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis","Comparative Study Between Fractional CO₂ Laser and 40% Urea Assisted Delivery of Topical Fluconazole Microemulsion in the Treatment of Onychomycosis","Inclusion Criteria:\n\n* Clinically and mycologically confirmed onychomycosis\n* No topical antifungal use in the past 1 month\n* No systemic antifungal use in the past 3 months\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* Nail disorders such as psoriasis, eczema, lichen planus\n* patients have a known allergy to any of the study treatments",true,"65 Years",{"count":77,"type":21},40,[52],"To evaluate the efficacy and safety of topical fluconazole microemulsion enhanced by fractional CO₂ laser versus by 40% urea ablation in treatment of Onychomycosis.",[27],"NOT_YET_RECRUITING","2025-06-25",{"date":84,"type":32},"2025-06-29",{"date":86,"type":21},"2025-06",{"date":88,"type":21},"2026-07",{"name":90,"class":91},"Assiut University","OTHER",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":40},"100541241","phase-2-a-study-of-atb1651-in-adults-with-mild-to-moderate-onchomycosis-100541241","NCT06327295","A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the","Inclusion Criteria:\n\n1. Confirmation of onychomycosis by positive mycological (KOH) staining and positive culture from affected great toenail(s).\n2. Appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s), as determined by visual inspection after the nail has been trimmed. If the percentage of infection is outside this range but is still considered appropriate for this study, based on the overall impression of the Principal Investigator (PI), participation can be considered in consultation with the Medical Monitor (MM). The visual inspection results of the appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s) will be reviewed by the Sponsor before enrollment.\n3. The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is \\\u003C 2 mm.\n4. Adult males and females, 18 to 70 years of age (inclusive) at the time of Screening.\n5. In good general health, with no significant medical history, and no clinically significant abnormalities on physical examination or ECG at Screening and\u002For before the first administration of IP at the discretion of the PI or designee. Participants with mild stable disease may be considered eligible at the discretion of the PI or designee.\n6. Body mass index (BMI) between 17.5 and 35.0 kg\u002Fm2, inclusive, at Screening.\n\nExclusion Criteria:\n\n1. History of allergy to any of the excipients in ATB1651.\n2. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening or Day 1.\n3. Underlying physical or psychological medical conditions that, in the opinion of the PI, would make it unlikely for the participant to comply with the protocol or complete the study per protocol.\n4. Unwilling to refrain from the use of nail cosmetics such as clear and\u002F or colored nail lacquers from the Screening visit until the end of the study.\n5. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to Screening.\n6. Diabetes mellitus requiring treatment other than diet and exercise.",{"count":100,"type":21},120,[102],"PHASE2","The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis",[27],"2025-02-17",{"date":107,"type":32},"2025-02-19",{"date":109,"type":32},"2024-07-01",{"date":111,"type":21},"2026-01-30",{"name":113,"class":66},"AmtixBio Co., Ltd."]